Stock since the trade -4.6% · S&P 500 +0.2% · to Oct 1Traded 41 days after resultsStock 51% above its 52-week low and 5% below its high
BMY · NYSE · Pharmaceuticals
Pharmaceuticals company based in New York City, New York.
Last close, Oct 1, 2026
$61.46
Adjusted for splits and dividends
Last 12 months
+29.6%
S&P 500 +14.3% over the same dates
Market value
$126B
Last close × shares outstanding
Bets against the stock: 42M shares sold short (2.1% of shares outstanding), -4.8% vs the previous count, 5.8 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$437K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$48.2B
-0.2% vs the year before
Net income, fiscal 2025
$7.05B
As reported in the annual filing
Shares outstanding
2.04B
As of Jul 22, 2026
In fiscal 2025 the company spent $5.04B on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade -4.6% · S&P 500 +0.2% · to Oct 1Traded 41 days after resultsStock 51% above its 52-week low and 5% below its high
Bristol Myers Squibb's Chief Med Offr,Head of Dev sold $403K of Bristol Myers Squibb shares. Nobody planned it ahead of time.
Officer plans to sell ~$403K of Bristol Myers Squibb
Planned, from payStock since the trade -9.5% · S&P 500 -0.3% · to Oct 1Traded 26 days after resultsStock at its 52-week high, after a 19% rise in the previous month
17K → 17K shares held−3% of their stake
Bristol Myers Squibb's SVP and Controller sold $34K of Bristol Myers Squibb shares. Nobody planned it ahead of time.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
6 different filers disclosed BMY within 90 days. Disclosed 477 days after the transaction; reported as an official range, not an exact amount.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
5 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
1 notice filed with state agencies, covering 133 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
124 certified in FY2026 Q3, vs 130 a year earlier. 124 positions in total, median offered wage $155K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last 12 months, adjusted daily closes
Adjusted close went from $47.43 on Oct 1, 2025 to $61.46 on Oct 1, 2026 (+29.6%). Disclosed trades in the last 12 months: 0 insider purchases, 4 insider sales (2 under pre-arranged plans), 3 Congress purchases, 4 Congress sales.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 153M shares
STATE STREET CORPORATION
Schedule 13G: passive · filed Aug 7, 2026 · 103M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Short sale volume: 49.9% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 44.9%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 74K shares (about $4.93M) were not delivered on time for settlement on Aug 24, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.